Luder H. Meyer

Ulm, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia.

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia.

Journal: Pediatric blood & cancer
Published: December 30, 2025

Therapeutic potential of BH3-mimetics and NK cell-mediated immunotherapy in T-ALL.

Therapeutic potential of BH3-mimetics and NK cell-mediated immunotherapy in T-ALL.

Journal: Cell death & disease
Published: May 15, 2025

A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity.

A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity.

Journal: Molecular therapy. Oncology
Published: May 02, 2025

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.

Journal: Leukemia
Published: December 02, 2024

Benchmarking miRNA reference genes in B-cell precursor acute lymphoblastic leukemia.

Benchmarking miRNA reference genes in B-cell precursor acute lymphoblastic leukemia.

Journal: Scientific reports
Published: July 17, 2024

The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL.

The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL.

Journal: Blood advances
Published: March 19, 2024

Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation.

Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation.

Journal: Cell death & disease
Published: November 17, 2023

Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion.

Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion.

Journal: Blood advances
Published: August 01, 2023

Discovery of fusion circular RNAs in leukemia with KMT2A::AFF1 rearrangements by the new software CircFusion.

Discovery of fusion circular RNAs in leukemia with KMT2A::AFF1 rearrangements by the new software CircFusion.

Journal: Briefings in bioinformatics
Published: August 05, 2022

Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.

Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.

Journal: Leukemia
Published: April 15, 2021

MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia.

MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia.

Journal: Frontiers in cell and developmental biology
Published: April 14, 2021

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.

Journal: Blood
Published: March 01, 2021
Showing 1-12 of 36

Last Updated: 09/26/2026